Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

BSH 2019 | Novel IMiD-based compounds and combinations

Sagar Lonial • 1 Apr 2019
BSH 2019
Multiple Myeloma

Speaking at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK, Sagar Lonial, MD, FACP, Emory University, Atlanta, GA, discusses the mechanism of action of IMiDs, and novel IMiD-based compounds and combinations in multiple myeloma.

More from Sagar Lonial

Practical advice for physicians treating patients with myeloma using belantamab mafodotin 0:37
Practical advice for physicians treating patients with myeloma using belantamab mafodotin
Sagar Lonial • 16 May 2025
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development 1:08
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development
Sagar Lonial • 16 May 2025
The ideal trial on the road to achieving the best outcome for patients with myeloma 0:41
The ideal trial on the road to achieving the best outcome for patients with myeloma
Sagar Lonial • 16 May 2025
The potential of CELMoDs for the treatment of multiple myeloma 0:50
The potential of CELMoDs for the treatment of multiple myeloma
Sagar Lonial • 16 May 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals